Associated Papers
A Retrospective Analysis of BCR-ABL1 Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory.
Majumdar A et al.
South Asian Journal of Cancer, 2024
BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India.
S A et al.
Leukemia Research Reports, 2024
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R et al.
Scientific Reports, 2022
35906470 (PubMed )
Supplement: 41598_2022_17271_MOESM2_ESM.pdf
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2020
[A multicenter comparison study on the detection of BCR-ABL tyrosine kinase domain point mutation].
Qin Y et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2015
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Machova Polakova K et al.
Journal of Cancer Research and Clinical Oncology, 2015
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Soverini S et al.
Blood, 2011
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW et al.
Blood, 2010
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2009
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
Azam M et al.
Cell, 2003
Select a paper to view details